Published in J Virol on October 01, 2004
Examining Factors That May Influence Resistance to HIV-1 Infection | NCT00351442
African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet (2008) 6.06
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe (2008) 2.85
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
Host factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology (2007) 1.77
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol (2006) 1.75
APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis (2009) 1.74
Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol (2008) 1.71
Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc Natl Acad Sci U S A (2010) 1.71
Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol (2008) 1.63
Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol (2006) 1.62
Intrinsic cellular defenses against human immunodeficiency viruses. Immunity (2012) 1.45
Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog (2010) 1.43
Gene expression variability within and between human populations and implications toward disease susceptibility. PLoS Comput Biol (2010) 1.39
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology (2008) 1.36
The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol (2011) 1.35
Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet (2010) 1.25
Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet (2007) 1.23
Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J Virol (2009) 1.23
Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog (2007) 1.22
T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog (2007) 1.19
The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int (2013) 1.11
Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity. PLoS Pathog (2009) 1.10
Regulatory polymorphisms in the cyclophilin A gene, PPIA, accelerate progression to AIDS. PLoS Pathog (2007) 1.08
APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS (2010) 1.08
The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J Exp Med (2009) 1.07
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03
Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A. J Biol Chem (2012) 1.02
Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain. J Biol Chem (2011) 0.99
Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids. J Virol (2010) 0.97
APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. Virology (2012) 0.97
Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression. AIDS (2011) 0.97
Polymorphisms of the SAMHD1 gene are not associated with the infection and natural control of HIV type 1 in Europeans and African-Americans. AIDS Res Hum Retroviruses (2012) 0.96
Host genetic determinants of human immunodeficiency virus infection and disease progression in children. Pediatr Res (2009) 0.96
NFAT and IRF proteins regulate transcription of the anti-HIV gene, APOBEC3G. J Biol Chem (2010) 0.94
The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization. PLoS One (2012) 0.92
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
Polymorphisms in eight host genes associated with control of HIV replication do not mediate elite control of viral replication in SIV-infected Indian rhesus macaques. Immunogenetics (2006) 0.90
Increased APOBEC3G and APOBEC3F expression is associated with low viral load and prolonged survival in simian immunodeficiency virus infected rhesus monkeys. Retrovirology (2011) 0.89
APOBEC3 Proteins in Viral Immunity. J Immunol (2015) 0.89
Genetic variants in the host restriction factor APOBEC3G are associated with HIV-1-related disease progression and central nervous system impairment in children. J Acquir Immune Defic Syndr (2013) 0.87
Are viruses inhibited by APOBEC3 molecules from their host species? PLoS Pathog (2009) 0.87
Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo. PLoS Pathog (2014) 0.87
Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment. Retrovirology (2012) 0.87
Evidence for selection at HIV host susceptibility genes in a West Central African human population. BMC Evol Biol (2012) 0.87
Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection. PLoS One (2008) 0.87
Identification and antiviral activity of common polymorphisms in the APOBEC3 locus in human populations. Virology (2013) 0.87
AID and APOBECs span the gap between innate and adaptive immunity. Front Microbiol (2014) 0.87
Host genetics influences on HIV type-1 disease. Antivir Ther (2009) 0.85
Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein. Viruses (2012) 0.85
A rare missense variant abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release. Retrovirology (2013) 0.84
Host genomic influences on HIV/AIDS. Genome Biol (2013) 0.84
APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans. Mol Biol Int (2012) 0.84
Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. Immunogenetics (2005) 0.82
Downregulation of APOBEC3G by xenotropic murine leukemia-virus related virus (XMRV) in prostate cancer cells. Virol J (2011) 0.80
Natural Single-Nucleotide Variations in the HIV-1 Genomic SA1prox Region Can Alter Viral Replication Ability by Regulating Vif Expression Levels. J Virol (2016) 0.79
Association of APOBEC3G genotypes and CD4 decline in Thai and Cambodian HIV-infected children with moderate immune deficiency. AIDS Res Ther (2012) 0.79
Accessory genes confer a high replication rate to virulent feline immunodeficiency virus. J Virol (2013) 0.77
APOBEC3G Variants and Protection against HIV-1 Infection in Burkina Faso. PLoS One (2016) 0.77
Codon pairs of the HIV-1 vif gene correlate with CD4+ T cell count. BMC Infect Dis (2013) 0.76
Natural Products as Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders (HAND): A Brief Overview. Front Microbiol (2016) 0.75
Functional characterization of Vif proteins from HIV-1 infected patients with different APOBEC3G haplotypes. AIDS (2016) 0.75
HBV/HIV co-infection and APOBEC3G polymorphisms in a population from Burkina Faso. BMC Infect Dis (2016) 0.75
Association between polymorphisms of the APOBEC3G gene and chronic hepatitis B viral infection and hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2017) 0.75
In vivo HIV-1 hypermutation and viral loads among antiretroviral-naive Brazilian patients. AIDS Res Hum Retroviruses (2014) 0.75
Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia. PLoS Genet (2016) 0.75
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet (1995) 13.84
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
THE INTERACTION OF SELECTION AND LINKAGE. II. OPTIMUM MODELS. Genetics (1964) 10.77
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 9.48
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med (2003) 8.40
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics (2002) 7.10
Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 6.20
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med (2001) 4.98
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04
Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep (1987) 3.66
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS (2001) 3.56
Long-term HIV-1 infection without immunologic progression. AIDS (1994) 3.41
Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA (1998) 2.37
Hemophilia growth and development study. Design, methods, and entry data. Am J Pediatr Hematol Oncol (1993) 2.28
Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. J Biol Chem (1995) 1.66
Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A (2002) 1.61
Acquired immune deficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type-1: the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (1992) 1.57
Polygenic and multifactorial disease gene association in man: Lessons from AIDS. Annu Rev Genet (2000) 1.24
NIRCA: a rapid robust method for screening for unknown point mutations. Biotechniques (1996) 1.07
A tumor necrosis factor-alpha-inducible promoter variant of interferon-gamma accelerates CD4+ T cell depletion in human immunodeficiency virus-1-infected individuals. J Infect Dis (2003) 0.93
MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment. J Infect Dis (2004) 0.84
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science (2010) 16.00
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
Methods for high-density admixture mapping of disease genes. Am J Hum Genet (2004) 12.02
A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet (2004) 10.87
Psychological sequelae of the September 11 terrorist attacks in New York City. N Engl J Med (2002) 10.07
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet (2008) 9.50
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet (2008) 9.00
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ (2007) 8.87
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
The influence of HLA genotype on AIDS. Annu Rev Med (2001) 7.77
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 7.58
WGAViewer: software for genomic annotation of whole genome association studies. Genome Res (2008) 7.15
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
Risk factors for HIV infection among men who have sex with men. AIDS (2006) 7.01
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Placental mammal diversification and the Cretaceous-Tertiary boundary. Proc Natl Acad Sci U S A (2003) 6.29
Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol (2003) 6.21
Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer (2008) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
Canadian illicit opiate users' views on methadone and other opiate prescription treatment: an exploratory qualitative study. Subst Use Misuse (2002) 5.65
A molecular phylogeny of living primates. PLoS Genet (2011) 5.61
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. AIDS (2009) 5.50
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health (2004) 5.21
Inhibition of hepatitis B virus replication by APOBEC3G. Science (2004) 5.15
APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00
APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 4.80
Merkel cell carcinoma and HIV infection. Lancet (2002) 4.72
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
High-risk behaviors among men who have sex with men in 6 US cities: baseline data from the EXPLORE Study. Am J Public Health (2003) 4.67
Initial sequence and comparative analysis of the cat genome. Genome Res (2007) 4.67
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) (2008) 4.38
Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol (2010) 4.34
Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction (2003) 4.25
The epidemiology of post-traumatic stress disorder after disasters. Epidemiol Rev (2005) 4.09
Advantage of rare HLA supertype in HIV disease progression. Nat Med (2003) 4.08
Television images and psychological symptoms after the September 11 terrorist attacks. Psychiatry (2002) 4.07
Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med (2004) 4.06
Mapping by admixture linkage disequilibrium: advances, limitations and guidelines. Nat Rev Genet (2005) 4.04
Substance use and sexual risk: a participant- and episode-level analysis among a cohort of men who have sex with men. Am J Epidemiol (2004) 4.03
KAP1 controls endogenous retroviruses in embryonic stem cells. Nature (2010) 4.02
Embryonic stem cell potency fluctuates with endogenous retrovirus activity. Nature (2012) 3.96
Trends of probable post-traumatic stress disorder in New York City after the September 11 terrorist attacks. Am J Epidemiol (2003) 3.93
Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science (2010) 3.92
Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ (2008) 3.85
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
In embryonic stem cells, ZFP57/KAP1 recognize a methylated hexanucleotide to affect chromatin and DNA methylation of imprinting control regions. Mol Cell (2011) 3.67
CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science (2003) 3.61
Genetic restoration of the Florida panther. Science (2010) 3.59
Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int (2009) 3.58
HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis (2007) 3.56
Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int (2012) 3.46
Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev (2002) 3.45
(Mis)use of factor analysis in the study of insulin resistance syndrome. Am J Epidemiol (2004) 3.43
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42
The social epidemiology of substance use. Epidemiol Rev (2004) 3.41
A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 3.41
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med (2003) 3.41
Challenges and facilitating factors in sustaining community-based participatory research partnerships: lessons learned from the Detroit, New York City and Seattle Urban Research Centers. J Urban Health (2006) 3.36
The late Miocene radiation of modern Felidae: a genetic assessment. Science (2006) 3.35
Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of san francisco men who have sex with men. J Urban Health (2005) 3.33
Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health (2004) 3.32
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS (2008) 3.31